AP NEWS

Canada Insulin Pump & CGM Market 2010-2018 & 2024: Users, Reimbursement Policy, Distribution Model, Training Model, Pricing Landscape, Diabetes, Diabetes & Population - ResearchAndMarkets.com

June 6, 2018

DUBLIN--(BUSINESS WIRE)--Jun 6, 2018--The “Canada Insulin Pump & CGM Market, Users, Reimbursement Policy (Government & Companies), Distribution Model, Training Model, Pricing Landscape, Diabetes, Diabetes (Type1 & 2) Population” report has been added to ResearchAndMarkets.com’s offering.

Although Canada insulin pump market is small, it has market potential to reach nearly CAD 1 Billion mark by the end of the year 2024

Similarly CGM market is also small but if it gets reimbursement under Canadian government then it has market potential to surpass CAD 80 Million by 2024. The government of Canada has expanded its diabetes management policy along with diabetes technology which will further boost the market for both insulin pump and continuous glucose monitoring (CGM) devices in Canada.

The study captures detailed analysis of insulin pump reimbursement policy of all 11 provinces. In Canada, insulin pump is reimbursed by provincial healthcare provider under the ministry of health. Each province provides their own insulin pump program to its citizen. Moreover, we have covered 11 provincial insulin pump programs with procedure and detailed information.

In addition there are many private insurers which also provide insulin pump reimbursement in Canada. We have covered 5 Private Insurer Reimbursement policies. All the 5 private insurers covered in the report are as follows: Sun Life Financial Great-West Life Assurance Company, Medavie Blue Cross, Green Shield Canada, & Manulife Financial.

Key Companies Covered:

1. Medtronic

2. Animas

3. OmniPod (Insulet Corporation)

Key Topics Covered:

1. Executive Summary

2. Diabetes Population (2010 - 2024)

2.1 Diabetes Cost on Canada Healthcare System

2.2 Total Diabetes Population

2.3 Insulin Dependent Diabetes Population

3. Insulin Pump Users & Continuous Glucose Monitoring (CGM) Users (2010 - 2024)

3.1 Insulin Pump Users (2010 - 2024)

3.2 Potential Insulin Pump User

3.3 CGM (Continuous Glucose Monitoring) User

3.4 Potential CGM Users (2010 - 2024)

4. Market Size & Projections (2010 - 2024)

4.1 Insulin Pump Market

4.2 Potential Insulin Pump Market

4.3 CGM Market & Forecast

4.4 Glucose Sensor Market & Forecast

4.5 CGM Transmitter Market & Forecast

4.6 Potential CGM Market

5. Competitive Analysis - Local Insights Sales, Marketing Structure & Promotional Activities (2016 - 2017)

5.1 Medtronic in Canada

5.2 Animas in Canada

5.3 OmniPod (Insulet Corporation) in Canada

6. Distribution Models

7. Differentiation Points of Insulin Pump Products in Canada

8. Training Model (Medtronic, Animas and Insulet Corp Training to Patients & HCP)

8.1 Medtronic

8.2 Insulet Canada Corporation (OmniPod)

8.3 Animas Corporation Canada

9. Current Struggles

9.1 Animas

9.2 Medtronic

9.3 Insulet Corporation

10. Pricing Landscape & Reimbursement (Insulin Pump, Insulin Pump + CGM, CGM)

10.1 Manufacturers - Pricing (By product)

10.2 Insulin Pump Integrated with CGM

10.3 Abbott Libre - Personal (if known) vs Professional use

11. Payers - Canada Pricing and Reimbursement Policies

11.1 Public Reimbursement details by Province

11.2 Eligibility Criteria for Coverage and Limitations

11.3 Canada All Provinces Insulin Pump Program Eligibility Criteria

11.4 Coverage for Supplies per Piece (Quantity Limits, $ Limits, Frequency Limits)

12. Top 5 Canadian Private Insurers Reimbursement Details

12.1 Great-West Life Assurance Company

12.2 Sun Life Financial

12.3 Medavie Blue Cross

12.4 Green Shield Canada

12.5 Manulife Financial

For more information about this report visit https://www.researchandmarkets.com/research/3g78nl/canada_insulin?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180606005644/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Diabetes Devices ,Infusions and Injectables ,Endocrinology

KEYWORD: NORTH AMERICA CANADA

INDUSTRY KEYWORD: HEALTH MEDICAL DEVICES DIABETES

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/06/2018 07:54 AM/DISC: 06/06/2018 07:54 AM

http://www.businesswire.com/news/home/20180606005644/en

AP RADIO
Update hourly